Over 1 million patients worldwide have trusted TAVR by Edwards—and that number continues to grow

James, a real TAVR patient, mountain climbing with a woman in the background


Less invasive. Less time in the hospital. Less pausing to recover. With TAVR by Edwards, there’s less waiting for your patients to return to what matters.1,2

In low-risk symptomatic severe aortic stenosis patients, TAVR offered more rapid recovery, short hospital stays, improved symptom relief, and improved heart function*1

One hour icon

TAVR is a minimally invasive procedure, with an average duration of 1 hour, and typically involves 1 small incision2

Icon of person standing next to a car

Most patients who receive TAVR by Edwards are discharged the following day2

Icon of a person standing inside of a house

9 of 10 patients are sent directly home vs to a care facility1

In a clinical study, TAVR by Edwards resulted in improved function, symptom relief (fatigue and shortness of breath, as well as increased physical capacity/walk distance), and quality of life at 30 days.1


The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.

PARTNER 3 Trial 5-Year Results in low-risk patients – Low rates of cardiovascular mortality through five years (5.5% SAPIEN 3 TAVR to 5.1% SAVR). Low rates of all-cause mortality through five years (10.1% SAPIEN 3 TAVR vs. 8.2% with SAVR). Low rates of disabling stroke through five years (2.9% SAPIEN 3 TAVR to 2.7% SAVR). Low rates of stroke through five years (5.8% SAPIEN 3 TAVR vs. 6.4% SAVR). Lower rates of rehospitalization with SAPIEN 3 TAVR through five years (13.7% vs. 17.4%).

TAVR by Edwards helps patients get back to their normal lives quickly.1

Peer Perspectives:

From surgeon to patient: Rick Dearman's story

“The procedure took under an hour. As far as recovery, I went home the next day.”

Dr. Richard Dearman
Real TAVR patient and cardiac surgeon


Durability and future access ensure that your patients experience sustained benefits.

References: 1.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 2.Cleveland Clinic. Transcatheter aortic valve replacement. Updated August 31, 2023. Accessed February 29, 2024. https://my.clevelandclinic.org/health/treatments/17570-transcatheter-aortic-valve-replacement-tavr. 3.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960.

Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.